Trends in lipoplex physical properties dependent on cationic lipid structure, vehicle and complexation procedure do not correlate with biological activity.
Using a group of structurally related cytofectins, the effects of different vehicle constituents and mixing techniques on the physical properties and biological activity of lipoplexes were systematically examined. Physical properties were examined using a combination of dye accessibility assays, centrifugation, gel electrophoresis and dynamic light scattering. Biological activity was examined using in vitro transfection. Lipoplexes were formulated using two injection vehicles commonly used for in vivo delivery (PBS pH 7.2 and 0.9% saline), and a sodium phosphate vehicle previously shown to enhance the biological activity of naked pDNA and lipoplex formulations. Phosphate was found to be unique in its effect on lipoplexes. Specifically, the accessible pDNA in lipoplexes formulated with cytofectins containing a gamma-amine substitution in the headgroup was dependent on alkyl side chain length and sodium phosphate concentration, but the same effects were not observed when using cytofectins containing a beta-OH headgroup substitution. The physicochemical features of the phosphate anion, which give rise to this effect in gamma-amine cytofectins, were deduced using a series of phosphate analogs. The effects of the formulation vehicle on transfection were found to be cell type-dependent; however, of the formulation variables examined, the liposome/pDNA mixing method had the greatest effect on transgene expression in vitro. Thus, though predictive physical structure relationships involving the vehicle and cytofectin components of the lipoplex were uncovered, they did not extrapolate to trends in biological activity.
Department of Chemistry, Vical Incorporated, 9373 Towne Centre Drive, Suite 100, San Diego, CA 92121, USA.
M E
ME
Ferrari
D
D
Rusalov
J
J
Enas
C J
CJ
Wheeler
D000818:Animals; D000838:Anions / Q000494:pharmacology; D002460:Cell Line; D004337:Drug Carriers; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes / Q000737:chemistry*; D010710:Phosphates / Q000494:pharmacology; D010957:Plasmids / Q000737:chemistry / Q000187:drug effects / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D012965:Sodium Chloride / Q000494:pharmacology; D013329:Structure-Activity Relationship; D014162:Transfection / Q000379:methods; D014407:Tumor Cells, Cultured; D001616:beta-Galactosidase / Q000187:drug effects / Q000235:genetics / Q000378:metabolism
D000838:Anions; D004337:Drug Carriers; D008055:Lipids; D008081:Liposomes; D010710:Phosphates; D011993:Recombinant Fusion Proteins; D012965:Sodium Chloride; D001616:beta-Galactosidase; C018279:sodium phosphate